From the Journals

Certain Women May Face Higher Risk for Second Breast Cancer


 

SOURCE:

This study, led by Kristen D. Brantley, PhD, from Harvard T. H. Chan School of Public Health, Boston, was published online in JAMA Oncology.

LIMITATIONS:

A small number of second breast cancer events limited the authors’ ability to assess the effects of multiple risk factors together. Data on risk factors might be incomplete. About 9% of participants completed abbreviated questionnaires that did not include information on body mass index, alcohol, smoking, and family history. Frequencies of pathogenic variants besides BRCA1 and BRCA2 may be underestimated.

DISCLOSURES:

This study received no external funding. Four authors reported receiving grants or royalties outside this work. Other reported no competing interests.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Ribociclib + Nonsteroidal Aromatase Inhibitor Improves Prognosis in HR+/HER2− Early BC
MDedge Hematology and Oncology
High TIL Levels Linked to Improved Prognosis in Early TNBC Even in Absence of Chemotherapy
MDedge Hematology and Oncology
Novel Treatment Sequence Speeds Up Breast Reconstruction Procedures in Patients With Breast Cancer
MDedge Hematology and Oncology
MRI-Based Strategy Can Limit Neoadjuvant Chemotherapy Duration in HR−/HER2+ BC
MDedge Hematology and Oncology
Breast Cancer Radiation Therapy Raises Risk for Nonkeratinocyte Skin Cancer
MDedge Hematology and Oncology
Antibiotic Exposure During Immunotherapy Increases Disease Burden in HER2− Early BC
MDedge Hematology and Oncology
Adjuvant Chemotherapy May be Omitted in Older Women Aged 80 Years or Older With HR+/HER2- BC
MDedge Hematology and Oncology
Impact of Adjuvant Ovarian Function Suppression on Recurrence Risk in Premenopausal HR+ Breast Cancer
MDedge Hematology and Oncology
Hormone + Radiation Therapy Better Than Either Treatment in Older Men With Early HR+ BC
MDedge Hematology and Oncology
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
MDedge Hematology and Oncology